Related Experiment Video
Updated: Jul 14, 2026
06:07
Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
Published on: June 23, 2023
Normal platelet mitochondrial complex I activity in Huntington's disease.
William J Powers1, Richard H Haas, Thuy Le
1Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA.
Neurobiology of Disease
|June 5, 2007
Summary
This study found no systemic defect in mitochondrial complex I activity in early Huntington's Disease (HD) patients, despite existing neuronal damage. These findings clarify previous conflicting research on platelet energy metabolism in HD.
Area of Science:
- Biochemistry
- Neuroscience
- Genetics
Background:
- Conflicting results exist from prior studies on platelet mitochondrial complex I activity in Huntington's Disease (HD).
- Assessing mitochondrial function in platelets may offer insights into systemic metabolic defects in neurodegenerative diseases like HD.
Purpose of the Study:
- To investigate platelet mitochondrial complex I and complex I/III activity in early gene-positive Huntington's Disease (HD).
- To resolve discrepancies in previous findings regarding mitochondrial complex I activity in HD.
Main Methods:
- Platelet mitochondrial complex I and complex I/III activity were measured in 21 early gene-positive HD subjects and 14 age-matched controls.
- A rigorous exclusion criterion (>10% reduction with 80% confidence) was applied to ensure reliable activity measurements.
Main Results:
- No significant systemic defect in platelet mitochondrial complex I activity was detected in early HD patients.
- The study's sample size (21 HD subjects) exceeds the combined total of previously published studies on platelet ETS activity in HD.
Conclusions:
- A systemic defect in mitochondrial complex I activity is not a feature of early Huntington's Disease, even when striatal neurodegeneration is present.
- These findings suggest that platelet mitochondrial assays may not reflect the specific bioenergetic deficits occurring in the early stages of HD striatal degeneration.
Related Concept Videos
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:48ATP Synthase: Mechanism
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased ATP...
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...